Form 4: Regulus Therapeutics Acquired by Novartis Subsidiary; Director Disposes of All Holdings

Regulus Therapeutics Inc. has been acquired by Redwood Merger Sub Inc., a Novartis AG subsidiary, resulting in the disposition of all common stock, options, and warrants held by Director Stelios Papadopoulos in exchange for cash and contingent value rights.

Summary

• Regulus Therapeutics Inc. was acquired by Redwood Merger Sub Inc., a wholly owned, indirect subsidiary of Novartis AG, effective June 25, 2025.
• The acquisition was completed via a cash tender offer for all outstanding common shares at an Offer Price of $7.00 in cash per share (Closing Amount) plus one Contingent Value Right (CVR) per share.
• Each CVR entitles the holder to an additional $7.00 in cash upon the achievement of a specified milestone.
• Director Stelios Papadopoulos disposed of all his common stock, stock options, and a common stock purchase warrant as a result of this merger.
• His 976,253 common shares were converted into the right to receive the Offer Price.
• In-the-Money stock options (exercise price less than $7.00) were canceled and converted into cash payments (Closing Amount minus exercise price) plus one CVR per underlying share.
• Out-of-the-Money stock options (exercise price equal to or greater than $7.00 but less than $14.00) were canceled and converted into one CVR per underlying share, with potential future cash payment if the milestone is met.
• A common stock purchase warrant was exchanged for $2.95 per warrant, based on its Black Scholes Value.

Sentiment

Score: 7

Explanation: The sentiment is generally positive for shareholders who received a cash premium and potential upside via CVRs. However, the contingent nature of the CVR introduces some uncertainty, preventing a higher score. For the company, it represents a successful acquisition by a major pharmaceutical player.

Positives

• Shareholders received a cash payment of $7.00 per share at closing.
• Shareholders also received a Contingent Value Right (CVR) for a potential additional $7.00 per share, offering upside potential.
• In-the-money stock options were cashed out, providing immediate value to option holders.
• The acquisition by Novartis AG provides a clear exit strategy and potential for the company's assets under a larger pharmaceutical entity.

Negatives

• The company, Regulus Therapeutics Inc., ceased to be an independent publicly traded entity, becoming a wholly owned subsidiary of Novartis AG.
• The full value of the CVR ($7.00) is contingent on a future milestone, introducing uncertainty.
• Out-of-the-money options only received CVRs, meaning no immediate cash payment for those specific options, and their value is entirely dependent on the milestone.
• If the CVR milestone is not met, no additional payment will be made for the CVRs or for the Out-of-the-Money Options.

Risks

• The Contingent Value Right (CVR) payment of $7.00 per share is contingent on the achievement of a specified milestone, and there is no guarantee that this milestone will be met.
• If the CVR milestone is not achieved, holders of CVRs and Out-of-the-Money Options will not receive the contingent cash payment.

Future Outlook

The future outlook for former Regulus Therapeutics shareholders includes the potential to receive an additional $7.00 per share via Contingent Value Rights (CVRs), contingent upon the achievement of a specific milestone. The former company is now a wholly-owned subsidiary of Novartis AG, indicating its future development will be integrated within Novartis's strategic plans.

Industry Context

This acquisition signifies a consolidation trend within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies like Novartis AG acquire smaller, specialized biotech firms to expand their pipeline and intellectual property. It reflects a strategic move by Novartis to potentially integrate Regulus's therapeutic assets, particularly those related to RNA-based medicines, into its broader drug development portfolio, reducing competition and leveraging synergies.

Comparison to Industry Standards

• This document is a Form 4 detailing an insider's transaction following a merger, not a financial performance report. Therefore, direct comparison to industry financial standards or specific comparable companies/projects is not applicable. The acquisition price and CVR structure would be evaluated against similar biotech M&A deals, but this document does not provide the necessary context for such a detailed comparison.

Stakeholder Impact

• **Shareholders**: Received $7.00 cash per share and one CVR per share, providing immediate liquidity and potential future upside. Former shareholders no longer hold equity in an independent public company.
• **Employees**: Regulus Therapeutics Inc. is now a wholly owned subsidiary of Novartis AG, which may lead to integration, restructuring, or changes in employment terms, though not explicitly stated in this filing.
• **Customers/Suppliers**: No direct impact mentioned, but integration into Novartis's larger supply chain and operational structure is likely.

Next Steps

• Achievement of the milestone specified in the CVR Agreement, which would trigger the contingent payment of $7.00 per CVR.
• Integration of Regulus Therapeutics Inc. as a wholly owned subsidiary into Novartis AG's operations.

Key Dates

Keywords

Regulus Therapeutics, Novartis AG, Merger Agreement, Tender Offer, SEC Form 4, Beneficial Ownership, Contingent Value Right, CVR, Stock Options, Warrants, Acquisition, Biotechnology, Pharmaceuticals